CTSO — Cytosorbents Cashflow Statement
0.000.00%
Last trade - 00:00- $58.85m
- $69.57m
- $35.59m
- 51
- 28
- 32
- 30
Annual cashflow statement for Cytosorbents, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.84 | -24.6 | -32.8 | -28.5 | -20.7 |
| Depreciation | |||||
| Non-Cash Items | 2.32 | 9.18 | 7.26 | 3.03 | 8.93 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.758 | 0.642 | -3.56 | 2.36 | -4.38 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -5.61 | -14 | -28.2 | -21.7 | -14.4 |
| Capital Expenditures | -1.68 | -4.28 | -6.46 | -0.936 | -0.669 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -1.68 | -4.28 | -6.46 | -0.936 | -0.669 |
| Financing Cash Flow Items | -0.375 | 0 | 0 | — | -0.848 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 66.3 | 0.715 | 4.96 | 14.5 | 9.33 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 59.2 | -17.6 | -30 | -8.22 | -5.85 |